JPMorgan Chase & Co. Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price

Edwards Lifesciences (NYSE:EW) had its price objective lifted by JPMorgan Chase & Co. from $100.00 to $105.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 24.97% from the company’s previous close.

A number of other research firms have also recently issued reports on EW. Truist Financial lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Piper Sandler reissued an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday. Citigroup raised their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.30.

Edwards Lifesciences Stock Up 0.2%

Shares of NYSE EW traded up $0.20 during mid-day trading on Friday, reaching $84.02. The company had a trading volume of 5,809,997 shares, compared to its average volume of 4,895,488. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company has a market capitalization of $48.38 billion, a price-to-earnings ratio of 44.68, a PEG ratio of 2.12 and a beta of 0.86. The stock has a fifty day moving average of $87.70 and a two-hundred day moving average of $83.89. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts expect that Edwards Lifesciences will post 3 EPS for the current year.

Insider Activity

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 45,577 shares of company stock valued at $3,855,527. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EW. Evermay Wealth Management LLC lifted its position in Edwards Lifesciences by 4.0% during the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after acquiring an additional 128 shares during the last quarter. Rehmann Capital Advisory Group increased its stake in shares of Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after purchasing an additional 130 shares during the period. Florida Trust Wealth Management Co increased its stake in shares of Edwards Lifesciences by 1.5% in the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after purchasing an additional 132 shares during the period. McIlrath & Eck LLC lifted its position in shares of Edwards Lifesciences by 14.6% during the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after purchasing an additional 135 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in Edwards Lifesciences by 0.9% during the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after purchasing an additional 136 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards beat Q2 estimates, reporting stronger-than-expected revenue and profit, which reinforced confidence in the company’s growth trajectory. Reuters article
• Positive Sentiment: Management raised the low end of full-year sales guidance, signaling better-than-expected demand and improving visibility for FY2026. WSJ article
• Positive Sentiment: Analysts highlighted the quarter as supportive of a bullish medtech thesis, with one firm upgrading EW to outperform and setting a higher price target, reflecting improving sentiment on the stock. The Fly article
• Neutral Sentiment: Q2 growth was driven by continued strength in TAVR and adoption of Edwards’ mitral and tricuspid therapies, which supports the company’s long-term growth narrative. Yahoo Finance article
• Neutral Sentiment: The company’s updated guidance was broadly in line with expectations for earnings, even as sales guidance improved, suggesting the market may focus more on revenue momentum than on near-term margin changes. MarketBeat earnings report

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.